AbbVie reports Phase 3 data for tavapadon in Parkinson’s disease
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
vzphotos/iStock Editorial via Getty Images
- AbbVie (NYSE:ABBV) reported positive topline results from a Phase 3 study of its drug tavapadon in the treatment of early Parkinson’s disease.
- The study, which evaluated tavapadon as a flexible-dose monotherapy, met its primary endpoint of showing statistically significant improvement from baseline